Amgen's third-quarter results showed robust performance, beating expectations in terms of revenue and earnings. While the company faces challenges such as potential scrutiny over ESAs, looming competitive threats in rheumathology, and some disappointing clinical results, positive factors include strong income, pipeline development, cost management, a solid balance sheet, and a reaffirmed patent position. The emphasis on denosumab commercialization and the attractive valuation post-performance suggest a positive short-term impact on the stock price.

[1]ocket
  on the stock price in the next 1â€“2 weeks.